Find the right trials. Reach the right people. Close deals faster.
SHR‑A1811 targets HER2-high, -low, and -mutant tumors, making it a prime CDx opportunity. Needs include HER2-low detection...
SHS‑B1811
Hengrui
China
SHR‑A1811 targets HER2-high, -low, and -mutant tumors, making it a prime CDx opportunity. Needs include HER2-low detection...
SHS‑B1811
Hengrui
China
91/100 Strategic Fit
Found 12 high-potential biotech companies with strong Phase 1 momentum and unmet NGS CDx needs.
Find me emerging biotech companies needing NGS CDx
FBTX-02 targeted to have Phase 1 readout in November 2025, with early readouts demonstrating favorable tolerability...
FBTX-014
FolioBio
USA
Phase 1
96/100 Strategic Fit
Identify
Spot high-priority leads before your competitors do
Allison McKenney
Chief Medical Officer
Warm Lead
Recently presented study results at ASCO 2025 and signaled search for CDx partner - prime time for outreach.
Dr. James Pavillion
VP of Translational Medicine
Warm Lead
Recently presented study results at ASCO 2025 and signaled search for CDx partner - prime time for outreach.
Subject:
CDx Collaboration for YX829508
Body:
Dr. Pavillion,
I saw your recent ASCO 2025 presentation and noted your mention of exploring CDx partnerships—especially timely given SHR-A3811’s broad activity across HER2-high, low, and mutant tumors..
Given the lack of a disclosed CDx partner and the need for NGS-based stratification and global diagnostic support, this could be a strong fit for a co-development opportunity. We’d love to explore how we might support your efforts ahead of Phase 2 planning.
Would you be open to a brief chat next week?
Best,
Davin
Rewrite
Send
Engage
Reach out with context that earns a response
Opportunities in Progress
PTRB-678
YK829508
First outreach by Abby to Dr. David Schofield re: CDx opportunity
01 June 2025
Zoom call for capabilities presentation
07 June 2025
Follow-up and thank you message sent. Waiting for response
10 June 2025
Response received - scheduling next in-person meeting
21 June 2025
Response received
21 June 2025
Log notes
Sync to SFDC
View Trial
Outreach
QRB7–4325
Track
Keep tabs on every opportunity—without the CRM bloat